These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 33030550)

  • 21. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
    Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
    Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome.
    Phillips K; Cirrone F; Ahuja T; Siegfried J; Papadopoulos J
    J Oncol Pharm Pract; 2019 Mar; 25(2):398-403. PubMed ID: 30319061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.
    Döring M; Cabanillas Stanchi KM; Queudeville M; Feucht J; Blaeschke F; Schlegel P; Feuchtinger T; Lang P; Müller I; Handgretinger R; Heinz WJ
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1281-1292. PubMed ID: 28258343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
    Heng SC; Slavin MA; Al-Badriyeh D; Kirsa S; Seymour JF; Grigg A; Thursky K; Bajel A; Nation RL; Kong DC
    J Antimicrob Chemother; 2013 Jul; 68(7):1669-78. PubMed ID: 23485723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of posaconazole for the prevention of invasive fungal infections in immunocompromised patients: a systematic review with meta-analysis and trial sequential analysis.
    Wong TY; Loo YS; Veettil SK; Wong PS; Divya G; Ching SM; Menon RK
    Sci Rep; 2020 Sep; 10(1):14575. PubMed ID: 32884060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Second- versus first-generation azoles for antifungal prophylaxis in hematology patients: a systematic review and meta-analysis.
    Ping B; Zhu Y; Gao Y; Yue C; Wu B
    Ann Hematol; 2013 Jun; 92(6):831-9. PubMed ID: 23455400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs.
    Wang JF; Xue Y; Zhu XB; Fan H
    Eur J Clin Microbiol Infect Dis; 2015 Apr; 34(4):651-9. PubMed ID: 25502737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is Posaconazole Really Effective in Adolescent patients as a Prophylactic Agent: Experience of a Tertiary Care Center.
    Arikan K; Aytac S; Büyükcam A; Cengiz AB; Cetinkaya FD; Cetin M; Ozsurekci Y; Ceyhan M; Kara A
    J Pediatr Hematol Oncol; 2021 Jul; 43(5):e613-e618. PubMed ID: 33560081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
    Busca A; Candoni A; Audisio E; Passera R; Bruno B; Monaco F; Mordini N; Vacca A; Delia M; Aversa F; Pagano L
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2214-2219. PubMed ID: 27667012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.
    Al-Badriyeh D; Slavin M; Liew D; Thursky K; Downey M; Grigg A; Bajel A; Stewart K; Kong DC
    J Antimicrob Chemother; 2010 May; 65(5):1052-61. PubMed ID: 20237074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
    Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
    J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of micafungin versus extensive azoles in the prevention and treatment of invasive fungal infections for neutropenia patients with hematological malignancies: A meta-analysis of randomized controlled trials.
    Lee CH; Lin JC; Ho CL; Sun M; Yen WT; Lin C
    PLoS One; 2017; 12(7):e0180050. PubMed ID: 28700646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011.
    Gomes MZ; Mulanovich VE; Jiang Y; Lewis RE; Kontoyiannis DP
    Antimicrob Agents Chemother; 2014; 58(2):865-73. PubMed ID: 24277033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breakthrough Invasive Fungal Infections in Patients With High-Risk Hematological Disorders Receiving Voriconazole and Posaconazole Prophylaxis: A Systematic Review.
    Boutin CA; Durocher F; Beauchemin S; Ziegler D; Abou Chakra CN; Dufresne SF
    Clin Infect Dis; 2024 Jul; 79(1):151-160. PubMed ID: 38752732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Newer antifungal agents micafungin and voriconazole for fungal infection prevention during hematopoietic cell transplantation: a meta-analysis.
    Xu SX; Shen JL; Tang XF; Feng B; Xu HQ
    Eur Rev Med Pharmacol Sci; 2016; 20(2):381-90. PubMed ID: 26875911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations.
    Cho SY; Lee DG; Choi SM; Choi JK; Lee HJ; Kim SH; Park SH; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS
    Mycoses; 2015 Sep; 58(9):565-71. PubMed ID: 26214656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.
    Ananda-Rajah MR; Grigg A; Downey MT; Bajel A; Spelman T; Cheng A; Thursky KT; Vincent J; Slavin MA
    Haematologica; 2012 Mar; 97(3):459-63. PubMed ID: 22058198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials.
    Ethier MC; Science M; Beyene J; Briel M; Lehrnbecher T; Sung L
    Br J Cancer; 2012 May; 106(10):1626-37. PubMed ID: 22568999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antifungal prophylaxis in adult hematopoietic stem cell transplant recipients.
    Tamura K; Drew R
    Drugs Today (Barc); 2008 Jul; 44(7):515-30. PubMed ID: 18806902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.
    Tverdek FP; Heo ST; Aitken SL; Granwehr B; Kontoyiannis DP
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.